Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Pradaxa Tablet Proton Pump Inhibitor (PPI) Bioavailability (BA) Study in Japan

Phase 1

Completed

Conditions: Non-alcoholic Fatty Liver Disease

Interventions: Drug: Dabigatran Etexilate
Drug: Rabeprazol sodium

First Posted Date: 2017-05-08

Last Posted Date: 2019-01-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 36

Registration Number: NCT03143166

Locations: 🇯🇵
Souseikai Hakata Clinic, Fukuoka, Fukuoka, Japan

BI 443651 Methacholine Challenge

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: Placebo
Drug: BI 443651

First Posted Date: 2017-05-02

Last Posted Date: 2019-11-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 37

Registration Number: NCT03135899

Locations: 🇬🇧
The Medicines Evaluation Unit, Manchester, United Kingdom

Health-related Quality of Life in Patients on Anticoagulants

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: DOAC or VKA
Drug: VKA

First Posted Date: 2017-05-01

Last Posted Date: 2019-04-18

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 535

Registration Number: NCT03134911

Locations: 🇪🇸
Hospital Universitario Príncipe de Asturias, Alcalá De Henares (Madrid), Spain
🇪🇸
Hospital Público Virgen de los Lirios, Alcoy (Alicante), Spain
🇪🇸
Hospital San Juan de Dios, Bormujos (Sevilla), Spain

and more 36 locations

Initial Dosing of BI 655130 in Palmoplantar Pustulosis Patients

Phase 2

Completed

Conditions: Psoriasis

Interventions: Drug: Spesolimab (low dose)
Drug: Spesolimab (high dose)
Drug: Placebo

First Posted Date: 2017-05-01

Last Posted Date: 2019-11-26

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 59

Registration Number: NCT03135548

Locations: 🇨🇦
York Dermatology Clinic and Research Centre, Richmond Hill, Ontario, Canada
🇨🇦
Innovaderm Research Inc., Montreal, Quebec, Canada
🇩🇰
Gentofte Hospital, Hellerup, Denmark

and more 15 locations

A Study in Patients With Mild or Moderate Ulcerative Colitis Who Take a TNF Inhibitor. The Study Investigates Whether Bowel Inflammation Improves When Patients Take BI 655130 in Addition to Their Current Therapy

Phase 2

Completed

Conditions: Colitis, Ulcerative

Interventions: Drug: Placebo
Drug: Spesolimab

First Posted Date: 2017-04-21

Last Posted Date: 2021-11-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 22

Registration Number: NCT03123120

Locations: 🇩🇰
Aalborg Sygehus Syd, Aalborg, Denmark
🇩🇰
Odense University Hospital, Odense, Denmark
🇪🇸
Hospital Puerta de Hierro, Majadahonda, Spain

and more 13 locations

Safety and Pharmacokinetics of Single Rising Doses of BI 705564 and Food Effect on BI 705564 in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 705564 (Test)
Drug: Placebo
Drug: BI 705564 (Reference)

First Posted Date: 2017-04-21

Last Posted Date: 2022-07-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 91

Registration Number: NCT03123185

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

Single Rising Dose Trial of Spesolimab (BI 655130) for Healthy Japanese Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Spesolimab
Drug: Placebo

First Posted Date: 2017-04-21

Last Posted Date: 2024-03-06

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 32

Registration Number: NCT03123094

Locations: 🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of

Safety and Tolerability of BI 685509 in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BI 685509

First Posted Date: 2017-04-17

Last Posted Date: 2018-06-11

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 60

Registration Number: NCT03116906

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

Drug-drug Interaction (DDI) With a P-gp Inhibitor, Organic Anion Transporting Polypeptide OATP-inhibitor, Food Effect

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 685509 Fasted Conditions
Drug: BI 685509 After Standardised Breakfast
Drug: Itraconazole
Drug: Rifampin

First Posted Date: 2017-04-17

Last Posted Date: 2017-06-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 15

Registration Number: NCT03116893

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

This Study Tests How Different Doses of BI 690517 Are Taken up in the Body of Healthy Men. The Study Also Looks at How Food Influences the Amount of BI 690517 in the Blood

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 690517
Drug: BI 690517 (Reference)
Drug: Placebo

First Posted Date: 2017-04-04

Last Posted Date: 2017-11-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 72

Registration Number: NCT03100916

Locations: 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy